Free Trial
→ Protect Your Bank Account with THESE 4 Simple Steps (From Weiss Ratings) (Ad) Free GILD Stock Alerts

Gilead Sciences (GILD) Financials

Gilead Sciences logo
$119.30 +9.02 (+8.18%)
As of 02:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Gilead Sciences

Annual Income Statements for Gilead Sciences

This table shows Gilead Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 12,101 18,108 13,501 4,628 5,455 5,386 123 6,225 4,592 5,665 480
Consolidated Net Income / (Loss)		 12,059 18,106 13,488 4,644 5,460 5,364 89 6,201 4,566 5,613 480
Net Income / (Loss) Continuing Operations		 12,059 18,106 13,488 4,644 5,460 5,364 89 6,201 4,566 5,612 479
Total Pre-Tax Income 		14,856 21,659 17,097 13,529 7,799 5,160 1,669 8,278 5,814 6,859 690
Total Operating Income		 15,265 22,193 17,633 14,124 8,200 4,287 4,071 9,918 7,330 7,605 1,662
Total Gross Profit		 21,102 28,633 26,129 21,736 17,274 17,774 20,117 20,704 21,624 20,618 22,503
Total Revenue		 24,890 32,639 30,390 26,107 22,127 22,449 24,689 27,305 27,281 27,116 28,754
Operating Revenue		 24,474 32,151 30,390 26,107 22,127 22,449 24,689 27,305 27,281 27,116 28,754
Total Cost of Revenue		 3,788 4,006 4,261 4,371 4,853 4,675 4,572 6,601 5,657 6,498 6,251
Operating Cost of Revenue		 3,788 4,006 4,261 4,371 4,853 4,675 4,572 6,601 5,657 6,498 6,251
Total Operating Expenses		 5,837 6,440 8,496 7,612 9,074 13,487 16,046 10,786 14,294 13,013 20,841
Selling, General & Admin Expense		 2,983 3,426 3,398 3,878 4,056 4,381 5,151 5,246 5,673 6,090 6,091
Research & Development Expense		 2,854 3,014 5,098 3,734 5,018 9,106 10,895 5,540 5,921 6,873 10,570
Impairment Charge		 - - - - - - 0.00 0.00 2,700 50 4,180
Total Other Income / (Expense), net		 -409 -534 -536 -595 -401 873 -2,402 -1,640 -1,516 -746 -971
Interest Expense		 412 688 964 1,118 1,077 995 984 1,001 935 944 977
Other Income / (Expense), net		 3.00 154 428 523 676 1,868 -1,418 -639 -581 198 6.00
Income Tax Expense		 2,797 3,553 3,609 8,885 2,339 -204 1,580 2,077 1,248 1,247 211
Net Income / (Loss) Attributable to Noncontrolling Interest		 -42 -2.00 -13 16 5.00 -22 -34 -24 -26 -52 0.00
Basic Earnings per Share		 $7.95 $12.37 $10.08 $3.54 $4.20 $4.24 $0.10 $4.96 $3.66 $4.54 $0.38
Weighted Average Basic Shares Outstanding		 1.52B 1.46B 1.34B 1.31B 1.30B 1.27B 1.26B 1.26B 1.26B 1.25B 1.25B
Diluted Earnings per Share		 $7.35 $11.91 $9.94 $3.51 $4.17 $4.22 $0.10 $4.93 $3.64 $4.50 $0.38
Weighted Average Diluted Shares Outstanding		 1.65B 1.52B 1.36B 1.32B 1.31B 1.28B 1.26B 1.26B 1.26B 1.26B 1.26B
Weighted Average Basic & Diluted Shares Outstanding		 1.52B 1.46B 1.34B 1.31B 1.30B 1.26B 1.26B 1.25B 1.25B 1.25B 1.25B
Cash Dividends to Common per Share		 $0.00 $1.29 $1.84 $2.08 $2.28 $2.52 $2.72 $2.84 $2.92 $3.00 $3.08

Quarterly Income Statements for Gilead Sciences

This table shows Gilead Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 1,640 1,010 1,045 2,180 1,430 -4,170 1,614 1,253 1,783 1,315 1,960
Consolidated Net Income / (Loss)		 1,633 985 1,039 2,172 1,417 -4,170 1,614 1,253 1,783 1,315 1,960
Net Income / (Loss) Continuing Operations		 1,633 984 1,039 2,172 1,417 -4,171 1,615 1,253 1,782 1,315 1,961
Total Pre-Tax Income 		2,031 1,300 1,588 2,318 1,653 -4,486 2,053 956 2,167 1,649 2,429
Total Operating Income		 2,267 1,705 1,665 2,623 1,612 -4,322 2,644 888 2,452 2,237 2,474
Total Gross Profit		 5,993 4,951 5,157 5,486 5,024 5,134 5,410 5,971 5,988 5,127 5,581
Total Revenue		 7,389 6,352 6,599 7,051 7,114 6,686 6,954 7,545 7,569 6,667 7,082
Operating Revenue		 7,389 6,352 6,599 7,051 7,114 6,686 6,954 7,545 7,569 6,667 7,082
Total Cost of Revenue		 1,396 1,401 1,442 1,565 2,090 1,552 1,544 1,574 1,581 1,540 1,501
Operating Cost of Revenue		 1,396 1,401 1,442 1,565 2,090 1,552 1,544 1,574 1,581 1,540 1,501
Total Operating Expenses		 3,726 3,247 3,492 2,863 3,411 9,456 2,766 5,083 3,536 2,890 3,107
Selling, General & Admin Expense		 2,020 1,319 1,849 1,315 1,607 1,375 1,377 1,433 1,906 1,258 1,365
Research & Development Expense		 1,706 1,928 1,643 1,548 1,754 5,651 1,389 1,900 1,630 1,632 1,552
Impairment Charge		 - 0.00 0.00 0.00 50 2,430 0.00 1,750 - 0.00 190
Total Other Income / (Expense), net		 -236 -404 -78 -304 40 -163 -592 68 -284 -588 -46
Interest Expense		 226 230 230 232 252 254 237 238 248 260 254
Other Income / (Expense), net		 -10 -174 152 -72 292 91 -355 306 -36 -328 208
Income Tax Expense		 398 316 549 146 236 -315 438 -297 385 334 468
Net Income / (Loss) Attributable to Noncontrolling Interest		 -7.00 -26 -6.00 -8.00 -12 0.00 0.00 0.00 - 0.00 0.00
Basic Earnings per Share		 $1.30 $0.81 $0.84 $1.75 $1.14 ($3.34) $1.29 $1.00 $1.43 $1.06 $1.57
Weighted Average Basic Shares Outstanding		 1.26B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B
Diluted Earnings per Share		 $1.29 $0.80 $0.83 $1.73 $1.14 ($3.34) $1.29 $1.00 $1.43 $1.04 $1.56
Weighted Average Diluted Shares Outstanding		 1.26B 1.26B 1.26B 1.26B 1.26B 1.25B 1.25B 1.25B 1.26B 1.26B 1.26B
Weighted Average Basic & Diluted Shares Outstanding		 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.24B 1.25B 1.25B 1.24B 1.24B

Annual Cash Flow Statements for Gilead Sciences

This table details how cash moves in and out of Gilead Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 7,914 2,824 -4,622 -778 10,437 -6,309 -5,634 -659 74 673 3,906
Net Cash From Operating Activities		 12,818 21,250 17,047 11,898 8,400 9,144 8,168 11,384 9,072 8,006 10,828
Net Cash From Continuing Operating Activities		 12,818 21,250 17,047 11,898 8,400 9,144 8,168 11,384 9,072 8,005 10,828
Net Income / (Loss) Continuing Operations		 12,059 18,106 13,488 4,644 5,460 5,364 89 6,201 4,566 5,613 480
Consolidated Net Income / (Loss)		 12,059 18,106 13,488 4,644 5,460 5,364 89 6,201 4,566 5,613 480
Depreciation Expense		 125 161 177 233 226 255 288 329 323 354 381
Amortization Expense		 925 937 981 1,053 1,203 1,149 1,192 1,721 1,780 2,339 2,386
Non-Cash Adjustments To Reconcile Net Income		 362 944 974 942 2,161 5,272 8,451 2,760 5,718 2,964 10,305
Changes in Operating Assets and Liabilities, net		 -653 1,102 1,427 5,026 -650 -2,896 -1,852 373 -3,315 -3,265 -2,724
Net Cash From Investing Activities		 -1,823 -12,475 -11,985 -16,069 14,355 -7,817 -14,615 -3,131 -2,466 -2,265 -3,449
Net Cash From Continuing Investing Activities		 -1,823 -12,475 -11,985 -16,069 14,355 -7,817 -14,615 -3,131 -2,466 -2,266 -3,449
Purchase of Property, Plant & Equipment		 -557 -747 -748 -590 -924 -825 -650 -579 -728 -585 -523
Acquisitions		 - 0.00 0.00 -10,426 0.00 -4,251 -25,920 -1,584 -1,797 -1,152 -4,840
Purchase of Investments		 -2,125 -17,239 -25,976 -23,314 -10,389 -32,228 -20,770 -3,897 -1,942 -2,372 -736
Sale and/or Maturity of Investments		 859 5,511 14,739 18,261 25,858 29,921 32,718 2,910 2,002 1,844 2,592
Other Investing Activities, net		 - - - 0.00 -190 -434 7.00 19 -1.00 -1.00 58
Net Cash From Financing Activities		 -3,025 -5,884 -9,725 3,393 -12,318 -7,634 770 -8,877 -6,469 -5,125 -3,433
Net Cash From Continuing Financing Activities		 -3,025 -5,884 -9,725 3,393 -12,318 -7,634 770 -8,877 -6,469 -5,126 -3,433
Repayment of Debt		 -8,872 -5,013 -2,257 -2,141 -6,736 -2,872 -2,638 -4,895 -1,673 -2,529 -2,251
Repurchase of Common Equity		 -5,349 -10,002 -11,001 -954 -2,900 -1,749 -1,583 -546 -1,396 -1,000 -1,150
Payment of Dividends		 35 -1,874 -2,455 -2,731 -2,971 -3,222 -3,449 -3,605 -3,709 -3,809 -3,918
Issuance of Debt		 7,932 9,902 5,293 8,985 0.00 - 8,184 0.00 0.00 1,980 3,464
Issuance of Common Equity		 331 319 208 234 289 209 256 169 309 232 422
Effect of Exchange Rate Changes		 -56 -67 41 - - -2.00 43 -35 -63 57 -40
Cash Interest Paid		 330 529 885 1,038 1,070 982 951 979 907 891 951
Cash Income Taxes Paid		 2,060 3,137 2,436 3,342 3,198 1,793 2,639 2,509 3,136 3,990 2,779

Quarterly Cash Flow Statements for Gilead Sciences

This table details how cash moves in and out of Gilead Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Change in Cash & Equivalents		 713 -476 768 1.00 380 -1,367 -1,946 2,264 4,955 -2,065 -2,783
Net Cash From Operating Activities		 2,567 1,744 2,338 1,755 2,169 2,219 1,325 4,309 2,975 1,757 827
Net Cash From Continuing Operating Activities		 2,567 1,745 2,337 1,756 2,167 2,219 1,324 4,309 2,976 1,758 827
Net Income / (Loss) Continuing Operations		 1,633 985 1,039 2,172 1,417 -4,170 1,614 1,253 1,783 1,315 1,960
Consolidated Net Income / (Loss)		 1,633 985 1,039 2,172 1,417 -4,170 1,614 1,253 1,783 1,315 1,960
Depreciation Expense		 83 94 83 86 91 94 98 94 95 97 93
Amortization Expense		 445 546 598 598 597 596 596 596 598 599 598
Non-Cash Adjustments To Reconcile Net Income		 627 965 507 517 975 6,158 728 2,300 396 979 368
Changes in Operating Assets and Liabilities, net		 -221 -845 110 -1,617 -913 -459 -1,712 66 104 -1,232 -2,192
Net Cash From Investing Activities		 -375 -826 -483 -229 -727 -2,207 -307 -710 -225 -415 -2,116
Net Cash From Continuing Investing Activities		 -375 -826 -483 -229 -728 -2,205 -309 -709 -226 -416 -2,116
Purchase of Property, Plant & Equipment		 -181 -109 -139 -122 -215 -105 -130 -141 -147 -104 -107
Acquisitions		 -218 -551 -243 -79 -279 -4,043 -152 -570 -75 -273 -21
Purchase of Investments		 -378 -652 -645 -395 -680 -654 -34 -9.00 -39 -16 -2,308
Sale and/or Maturity of Investments		 400 491 545 361 447 2,592 - - - 0.00 310
Other Investing Activities, net		 2.00 -5.00 -1.00 6.00 -1.00 5.00 7.00 11 35 -23 10
Net Cash From Financing Activities		 -1,554 -1,406 -1,101 -1,519 -1,099 -1,361 -2,953 -1,379 2,260 -3,426 -1,567
Net Cash From Continuing Financing Activities		 -1,554 -1,407 -1,100 -1,519 -1,100 -1,360 -2,954 -1,379 2,260 -3,426 -1,567
Repayment of Debt		 -23 -135 -32 -2,328 -34 -116 -1,887 -194 -54 -1,938 -73
Repurchase of Common Equity		 -792 -400 -150 -300 -150 -400 -100 -300 -350 -730 -527
Payment of Dividends		 -915 -969 -944 -953 -943 -990 -972 -983 -973 -1,010 -994
Issuance of Common Equity		 176 97 26 83 26 146 5.00 98 173 252 27
Effect of Exchange Rate Changes		 75 13 13 -6.00 37 -18 -11 44 -55 19 73

Annual Balance Sheets for Gilead Sciences

This table presents Gilead Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 34,664 51,716 56,977 70,283 63,675 61,627 68,407 67,952 63,171 62,125 58,995
Total Current Assets		 17,714 24,762 19,588 31,823 35,836 30,296 15,996 14,772 14,443 16,085 19,173
Cash & Equivalents		 10,027 12,851 8,229 7,588 17,940 11,631 5,997 5,338 5,412 6,085 9,991
Short-Term Investments		 101 1,756 3,666 17,922 12,149 12,721 1,411 1,182 973 1,179 0.00
Accounts Receivable		 4,635 5,854 4,514 3,851 3,327 3,582 4,892 4,493 4,777 4,660 4,420
Inventories, net		 1,386 1,955 1,587 801 814 922 1,683 1,618 1,507 1,787 1,710
Prepaid Expenses		 1,057 1,518 1,592 1,661 1,606 1,440 2,013 2,141 1,774 2,374 3,052
Plant, Property, & Equipment, net		 1,674 2,276 2,865 3,295 4,006 4,502 4,967 5,121 5,475 5,317 5,414
Total Noncurrent Assets		 15,276 24,678 34,524 35,165 23,833 26,829 47,444 48,059 43,253 40,723 34,409
Long-Term Investments		 1,598 11,601 20,485 11,184 1,423 1,488 502 1,309 1,245 1,163 0.00
Goodwill		 1,172 1,172 1,172 4,159 4,117 4,117 8,108 8,332 8,314 8,314 8,314
Intangible Assets		 11,073 10,247 8,971 17,100 15,738 13,786 33,126 33,455 28,894 26,454 19,948
Noncurrent Deferred & Refundable Income Taxes		 236 324 - - - - - - - - 2,378
Other Noncurrent Operating Assets		 1,197 1,334 3,896 2,722 2,555 7,438 5,708 4,963 4,800 4,792 3,769
Total Liabilities & Shareholders' Equity		 34,664 51,716 56,977 70,283 63,675 61,627 68,407 67,952 63,171 62,125 58,995
Total Liabilities		 18,830 32,601 37,614 49,782 42,141 38,977 50,186 46,888 41,962 39,376 39,749
Total Current Liabilities		 5,761 9,890 9,218 11,635 10,605 9,759 11,397 11,610 11,237 11,280 12,004
Short-Term Debt		 483 982 0.00 2,747 2,748 2,499 2,757 1,516 2,273 1,798 1,815
Accounts Payable		 955 1,178 1,206 814 790 713 5,180 705 905 550 833
Accrued Expenses		 4,189 7,290 8,012 8,074 7,067 6,547 3,460 3,244 3,479 3,802 3,892
Other Current Liabilities		 - - - - - - - 6,145 4,580 5,130 5,464
Total Noncurrent Liabilities		 13,069 22,711 28,396 38,147 31,536 29,218 38,789 35,278 30,725 28,096 27,745
Long-Term Debt		 11,921 21,073 26,346 30,795 24,574 22,094 28,645 25,179 22,957 23,189 24,896
Noncurrent Deferred Revenue		 562 1,243 1,753 6,794 5,922 6,115 5,016 4,767 3,916 2,039 830
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - 3,914 4,356 2,673 1,588 724
Other Noncurrent Operating Liabilities		 586 395 297 558 1,040 1,009 1,214 976 1,179 1,280 1,295
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 15,819 19,113 19,363 20,501 21,534 22,650 18,221 21,064 21,209 22,749 19,246
Total Preferred & Common Equity		 15,426 18,534 18,887 20,442 21,387 22,525 18,202 21,069 21,240 22,833 19,330
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 15,426 18,534 18,887 20,442 21,387 22,525 18,202 21,069 21,240 22,833 19,330
Common Stock		 2,393 445 455 1,265 2,283 3,052 3,881 4,662 5,551 6,501 7,701
Retained Earnings		 12,732 18,001 18,154 19,012 19,024 19,388 14,381 16,324 15,687 16,304 11,497
Accumulated Other Comprehensive Income / (Loss)		 301 88 278 165 80 85 -60 83 2.00 28 132
Noncontrolling Interest		 393 579 476 59 147 125 19 -5.00 -31 -84 -84

Quarterly Balance Sheets for Gilead Sciences

This table presents Gilead Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Total Assets		 63,171 61,876 62,337 62,373 62,125 56,292 53,579 54,525 58,995 56,434 55,721
Total Current Assets		 14,443 13,456 14,287 15,980 16,085 14,041 12,317 14,779 19,173 16,901 14,718
Cash & Equivalents		 5,412 4,936 5,704 5,705 6,085 4,718 2,772 5,037 9,991 7,926 5,144
Short-Term Investments		 973 936 963 1,159 1,179 0.00 0.00 0.00 0.00 - 69
Accounts Receivable		 4,777 4,162 4,229 4,790 4,660 4,669 4,663 4,587 4,420 4,388 4,781
Inventories, net		 1,507 1,576 1,633 1,663 1,787 1,853 2,026 1,869 1,710 1,759 1,825
Prepaid Expenses		 1,774 1,846 1,757 2,662 2,374 2,800 2,856 3,287 3,052 2,828 2,899
Plant, Property, & Equipment, net		 5,475 5,479 5,540 5,572 5,317 5,321 5,346 5,391 5,414 5,421 5,459
Total Noncurrent Assets		 43,253 42,941 42,511 40,822 40,723 36,930 35,916 34,354 34,408 34,112 35,545
Long-Term Investments		 1,245 1,327 1,334 1,156 1,163 0.00 0.00 0.00 0.00 - 1,913
Goodwill		 8,314 8,314 8,314 8,314 8,314 8,314 8,314 8,314 8,314 8,314 8,314
Intangible Assets		 28,894 28,348 27,750 27,152 26,454 23,428 22,832 20,546 19,948 19,355 18,566
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - - 2,572 2,721
Other Noncurrent Operating Assets		 4,800 4,952 5,113 4,200 4,792 5,188 4,770 5,494 6,146 3,871 4,031
Total Liabilities & Shareholders' Equity		 63,171 61,876 62,337 62,373 62,125 56,292 53,579 54,525 58,995 56,434 55,721
Total Liabilities		 41,962 40,937 41,243 40,130 39,376 38,837 35,384 36,134 39,749 37,355 36,130
Total Current Liabilities		 11,237 10,528 13,964 11,945 11,280 13,015 10,781 11,725 12,004 12,344 11,189
Short-Term Debt		 2,273 2,283 4,037 1,793 1,798 3,667 1,810 1,812 1,815 2,806 2,806
Accounts Payable		 905 627 622 586 550 622 537 903 833 737 582
Accrued Expenses		 3,479 3,477 3,494 3,714 3,802 4,263 3,923 4,113 3,892 4,185 4,215
Other Current Liabilities		 4,580 4,140 5,810 5,852 5,130 4,464 4,510 4,896 5,464 4,615 3,586
Total Noncurrent Liabilities		 30,725 30,409 27,279 28,185 28,096 25,822 24,603 24,409 27,745 25,011 24,941
Long-Term Debt		 22,957 22,956 21,209 23,189 23,189 21,527 21,540 21,437 24,896 22,146 22,140
Noncurrent Deferred Revenue		 3,916 3,775 2,610 2,088 2,039 1,967 738 782 830 819 859
Noncurrent Deferred & Payable Income Tax Liabilities		 2,673 2,401 2,106 1,984 1,588 933 907 794 724 709 652
Other Noncurrent Operating Liabilities		 1,179 1,277 1,354 924 1,280 1,395 1,418 1,396 1,295 1,337 1,290
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 21,209 20,939 21,094 22,242 22,749 17,455 18,197 18,390 19,246 19,078 19,590
Total Preferred & Common Equity		 21,240 20,997 21,158 22,314 22,833 17,539 18,281 18,475 19,330 19,162 19,674
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 21,240 20,997 21,157 22,313 22,833 17,539 18,281 18,474 19,330 19,162 19,675
Common Stock		 5,551 5,794 6,009 6,280 6,501 6,814 7,023 7,328 7,701 8,139 8,368
Retained Earnings		 15,687 15,223 15,138 16,002 16,304 10,656 11,165 11,073 11,497 10,931 11,325
Accumulated Other Comprehensive Income / (Loss)		 2.00 -20 10 31 28 69 93 73 132 92 -18
Noncontrolling Interest		 -31 -58 -64 -72 -84 -84 -84 -84 -84 -84 -84

Annual Metrics And Ratios for Gilead Sciences

This table displays calculated financial ratios and metrics derived from Gilead Sciences' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 122.19% 31.13% -6.89% -14.09% -15.25% 1.46% 9.98% 10.60% -0.09% -0.60% 6.04%
EBITDA Growth		 235.76% 43.68% -18.03% -17.10% -35.32% -26.65% -45.32% 174.11% -21.86% 18.57% -57.75%
EBIT Growth		 238.16% 46.36% -19.18% -18.90% -39.40% -30.66% -56.90% 249.76% -27.27% 15.62% -78.62%
NOPAT Growth		 277.02% 49.72% -25.02% -65.15% 18.41% -22.37% -95.13% 3,322.36% -22.52% 8.09% -81.46%
Net Income Growth		 294.47% 50.15% -25.51% -65.57% 17.57% -1.76% -98.34% 6,867.42% -26.37% 22.93% -91.45%
EPS Growth		 306.08% 62.04% -16.54% -64.69% 18.80% 1.20% -97.63% 4,830.00% -26.17% 23.63% -91.56%
Operating Cash Flow Growth		 312.82% 65.78% -19.78% -30.20% -29.40% 8.86% -10.67% 39.37% -20.31% -11.75% 35.25%
Free Cash Flow Firm Growth		 351.10% 71.04% -22.68% -94.67% 593.73% -93.08% -5,155.00% 145.85% -25.35% -16.80% -21.42%
Invested Capital Growth		 4.02% -9.39% -10.91% 30.16% -0.03% 23.40% 94.89% -4.27% -2.81% 1.29% -8.50%
Revenue Q/Q Growth		 20.26% 3.79% -3.76% -4.99% -0.69% 0.38% 6.66% -0.64% 0.53% -1.00% 1.61%
EBITDA Q/Q Growth		 25.55% 5.92% -7.10% -9.42% -10.34% 12.89% 0.34% -7.93% 16.49% -1.81% 13.20%
EBIT Q/Q Growth		 26.25% 6.21% -7.58% -10.74% -11.47% 16.48% -2.32% -10.46% 22.96% -4.33% 44.29%
NOPAT Q/Q Growth		 27.77% 7.52% -10.57% -59.59% 237.55% 63.99% -87.71% -19.08% 31.63% -6.46% 116.70%
Net Income Q/Q Growth		 28.51% 7.24% -10.52% -59.89% 236.83% 100.30% -92.79% -15.85% 37.99% -3.71% 321.05%
EPS Q/Q Growth		 18.36% 3.03% -7.71% -60.02% 239.02% 100.95% -89.80% -16.16% 37.36% -3.23% 322.22%
Operating Cash Flow Q/Q Growth		 21.80% 15.01% -11.69% -6.20% -4.63% 2.64% -7.52% 12.77% -6.57% -4.74% 8.04%
Free Cash Flow Firm Q/Q Growth		 19.45% 12.90% -12.65% -92.90% 224.28% -79.35% -1,614.20% 174.14% -6.50% -15.66% 43.51%
Invested Capital Q/Q Growth		 5.78% -0.64% 3.97% 31.87% -10.97% 5.57% 101.40% -5.65% -1.34% 0.27% -1.74%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 84.78% 87.73% 85.98% 83.26% 78.07% 79.18% 81.48% 75.82% 79.26% 76.04% 78.26%
EBITDA Margin		 65.56% 71.83% 63.24% 61.03% 46.57% 33.67% 16.74% 41.49% 32.45% 38.71% 15.42%
Operating Margin		 61.33% 68.00% 58.02% 54.10% 37.06% 19.10% 16.49% 36.32% 26.87% 28.05% 5.78%
EBIT Margin		 61.34% 68.47% 59.43% 56.10% 40.11% 27.42% 10.75% 33.98% 24.74% 28.78% 5.80%
Profit (Net Income) Margin		 48.45% 55.47% 44.38% 17.79% 24.68% 23.89% 0.36% 22.71% 16.74% 20.70% 1.67%
Tax Burden Percent		 81.17% 83.60% 78.89% 34.33% 70.01% 103.95% 5.33% 74.91% 78.53% 81.83% 69.57%
Interest Burden Percent		 97.30% 96.92% 94.66% 92.37% 87.87% 83.83% 62.91% 89.21% 86.15% 87.90% 41.37%
Effective Tax Rate		 18.83% 16.40% 21.11% 65.67% 29.99% -3.95% 94.67% 25.09% 21.47% 18.18% 30.58%
Return on Invested Capital (ROIC)		 76.52% 117.89% 98.34% 31.61% 33.09% 23.00% 0.69% 18.20% 14.62% 15.93% 3.07%
ROIC Less NNEP Spread (ROIC-NNEP)		 62.52% 143.58% 106.64% 36.05% 40.74% -10.38% -0.46% 12.40% 8.09% 12.36% -0.98%
Return on Net Nonoperating Assets (RNNOA)		 10.73% -14.28% -28.23% -8.31% -7.12% 1.28% -0.25% 13.37% 6.98% 9.61% -0.78%
Return on Equity (ROE)		 87.25% 103.61% 70.11% 23.30% 25.98% 24.28% 0.44% 31.57% 21.60% 25.54% 2.29%
Cash Return on Invested Capital (CROIC)		 72.58% 127.74% 109.89% 5.40% 33.12% 2.05% -63.67% 22.57% 17.47% 14.65% 11.95%
Operating Return on Assets (OROA)		 53.34% 51.74% 33.23% 23.02% 13.25% 9.82% 4.08% 13.61% 10.29% 12.46% 2.75%
Return on Assets (ROA)		 42.13% 41.92% 24.82% 7.30% 8.15% 8.56% 0.14% 9.10% 6.96% 8.96% 0.79%
Return on Common Equity (ROCE)		 84.57% 100.68% 68.18% 22.99% 25.85% 24.13% 0.43% 31.56% 21.62% 25.60% 2.30%
Return on Equity Simple (ROE_SIMPLE)		 78.17% 97.69% 71.41% 22.72% 25.53% 23.81% 0.49% 29.43% 21.50% 24.58% 2.48%
Net Operating Profit after Tax (NOPAT)		 12,391 18,552 13,911 4,848 5,741 4,456 217 7,430 5,757 6,222 1,154
NOPAT Margin		 49.78% 56.84% 45.77% 18.57% 25.94% 19.85% 0.88% 27.21% 21.10% 22.95% 4.01%
Net Nonoperating Expense Percent (NNEP)		 14.00% -25.69% -8.30% -4.45% -7.65% 33.38% 1.15% 5.80% 6.53% 3.57% 4.05%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 12.40% 13.04% 2.51%
Cost of Revenue to Revenue		 15.22% 12.27% 14.02% 16.74% 21.93% 20.83% 18.52% 24.18% 20.74% 23.96% 21.74%
SG&A Expenses to Revenue		 11.98% 10.50% 11.18% 14.85% 18.33% 19.52% 20.86% 19.21% 20.79% 22.46% 21.18%
R&D to Revenue		 11.47% 9.23% 16.78% 14.30% 22.68% 40.56% 44.13% 20.29% 21.70% 25.35% 36.76%
Operating Expenses to Revenue		 23.45% 19.73% 27.96% 29.16% 41.01% 60.08% 64.99% 39.50% 52.40% 47.99% 72.48%
Earnings before Interest and Taxes (EBIT)		 15,268 22,347 18,061 14,647 8,876 6,155 2,653 9,279 6,749 7,803 1,668
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 16,318 23,445 19,219 15,933 10,305 7,559 4,133 11,329 8,852 10,496 4,435
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.70 5.79 3.76 3.55 3.02 3.03 3.46 3.89 4.69 4.25 5.96
Price to Tangible Book Value (P/TBV)		 32.50 15.08 8.12 0.00 42.21 14.76 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 4.15 3.29 2.34 2.78 2.92 3.04 2.55 3.00 3.65 3.58 4.00
Price to Earnings (P/E)		 8.54 5.92 5.26 15.66 11.85 12.67 512.71 13.17 21.69 17.12 239.83
Dividend Yield		 0.00% 1.73% 3.41% 3.75% 4.56% 4.67% 5.41% 4.34% 3.68% 3.85% 3.33%
Earnings Yield		 11.71% 16.88% 19.01% 6.39% 8.44% 7.90% 0.20% 7.59% 4.61% 5.84% 0.42%
Enterprise Value to Invested Capital (EV/IC)		 6.33 6.93 4.91 4.00 3.49 3.13 2.08 2.53 3.02 2.89 3.66
Enterprise Value to Revenue (EV/Rev)		 4.20 3.18 2.15 2.66 2.74 2.99 3.51 3.69 4.30 4.18 4.58
Enterprise Value to EBITDA (EV/EBITDA)		 6.40 4.42 3.41 4.36 5.88 8.88 20.95 8.90 13.24 10.81 29.71
Enterprise Value to EBIT (EV/EBIT)		 6.84 4.64 3.62 4.74 6.83 10.90 32.63 10.87 17.36 14.54 78.99
Enterprise Value to NOPAT (EV/NOPAT)		 8.43 5.59 4.70 14.31 10.56 15.06 398.80 13.58 20.35 18.23 114.19
Enterprise Value to Operating Cash Flow (EV/OCF)		 8.15 4.88 3.84 5.83 7.22 7.34 10.60 8.86 12.92 14.17 12.17
Enterprise Value to Free Cash Flow (EV/FCFF)		 8.89 5.16 4.21 83.78 10.55 168.80 0.00 10.95 17.04 19.83 29.30
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.78 1.15 1.36 1.64 1.27 1.09 1.72 1.27 1.19 1.10 1.39
Long-Term Debt to Equity		 0.75 1.10 1.36 1.50 1.14 0.98 1.57 1.20 1.08 1.02 1.29
Financial Leverage		 0.17 -0.10 -0.26 -0.23 -0.17 -0.12 0.54 1.08 0.86 0.78 0.79
Leverage Ratio		 2.07 2.47 2.82 3.19 3.19 2.84 3.18 3.47 3.10 2.85 2.88
Compound Leverage Factor		 2.01 2.40 2.67 2.95 2.80 2.38 2.00 3.10 2.67 2.51 1.19
Debt to Total Capital		 43.93% 53.57% 57.64% 62.07% 55.92% 52.06% 63.28% 55.90% 54.33% 52.34% 58.12%
Short-Term Debt to Total Capital		 1.71% 2.39% 0.00% 5.08% 5.62% 5.29% 5.56% 3.17% 4.89% 3.77% 3.95%
Long-Term Debt to Total Capital		 42.22% 51.19% 57.64% 56.98% 50.30% 46.77% 57.73% 52.72% 49.43% 48.58% 54.17%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 1.44% 1.41% 1.04% 0.11% 0.30% 0.26% 0.04% -0.01% -0.07% -0.18% -0.18%
Common Equity to Total Capital		 54.63% 45.02% 41.32% 37.83% 43.78% 47.68% 36.68% 44.12% 45.74% 47.83% 42.06%
Debt to EBITDA		 0.76 0.94 1.37 2.11 2.65 3.25 7.60 2.36 2.85 2.38 6.02
Net Debt to EBITDA		 0.04 -0.18 -0.31 -0.20 -0.41 -0.17 5.68 1.67 1.99 1.58 3.77
Long-Term Debt to EBITDA		 0.73 0.90 1.37 1.93 2.38 2.92 6.93 2.22 2.59 2.21 5.61
Debt to NOPAT		 1.00 1.19 1.89 6.92 4.76 5.52 144.65 3.59 4.38 4.02 23.15
Net Debt to NOPAT		 0.05 -0.22 -0.43 -0.65 -0.73 -0.28 108.21 2.54 3.06 2.66 14.49
Long-Term Debt to NOPAT		 0.96 1.14 1.89 6.35 4.28 4.96 131.95 3.39 3.99 3.73 21.58
Altman Z-Score		 6.39 4.86 3.38 2.66 2.62 2.58 1.62 2.29 2.62 2.79 2.74
Noncontrolling Interest Sharing Ratio		 3.06% 2.83% 2.75% 1.34% 0.49% 0.62% 0.35% 0.04% -0.09% -0.26% -0.40%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.07 2.50 2.13 2.74 3.38 3.10 1.40 1.27 1.29 1.43 1.60
Quick Ratio		 2.56 2.07 1.78 2.52 3.15 2.86 1.08 0.95 0.99 1.06 1.20
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 11,753 20,102 15,544 828 5,746 397 -20,093 9,213 6,878 5,722 4,497
Operating Cash Flow to CapEx		 2,301.26% 2,844.71% 2,279.01% 2,016.61% 909.09% 1,108.36% 1,256.62% 1,966.15% 1,246.15% 1,368.55% 2,070.36%
Free Cash Flow to Firm to Interest Expense		 28.53 29.22 16.12 0.74 5.33 0.40 -20.42 9.20 7.36 6.06 4.60
Operating Cash Flow to Interest Expense		 31.11 30.89 17.68 10.64 7.80 9.19 8.30 11.37 9.70 8.48 11.08
Operating Cash Flow Less CapEx to Interest Expense		 29.76 29.80 16.91 10.11 6.94 8.36 7.64 10.79 8.92 7.86 10.55
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.87 0.76 0.56 0.41 0.33 0.36 0.38 0.40 0.42 0.43 0.47
Accounts Receivable Turnover		 7.30 6.22 5.86 6.24 6.17 6.50 5.83 5.82 5.89 5.75 6.33
Inventory Turnover		 2.46 2.40 2.41 3.66 6.01 5.39 3.51 4.00 3.62 3.95 3.58
Fixed Asset Turnover		 17.53 16.53 11.82 8.48 6.06 5.28 5.21 5.41 5.15 5.03 5.36
Accounts Payable Turnover		 3.43 3.76 3.57 4.33 6.05 6.22 1.55 2.24 7.03 8.93 9.04
Days Sales Outstanding (DSO)		 49.98 58.65 62.26 58.48 59.20 56.17 62.64 62.73 62.01 63.51 57.63
Days Inventory Outstanding (DIO)		 148.53 152.20 151.71 99.70 60.73 67.77 103.98 91.26 100.82 92.51 102.10
Days Payable Outstanding (DPO)		 106.52 97.17 102.11 84.34 60.32 58.67 235.23 162.70 51.94 40.86 40.38
Cash Conversion Cycle (CCC)		 92.00 113.68 111.86 73.84 59.62 65.26 -68.61 -8.71 110.89 115.16 119.35
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 16,512 14,962 13,329 17,349 17,344 21,403 41,713 39,930 38,809 39,309 35,966
Invested Capital Turnover		 1.54 2.07 2.15 1.70 1.28 1.16 0.78 0.67 0.69 0.69 0.76
Increase / (Decrease) in Invested Capital		 638 -1,550 -1,633 4,020 -5.00 4,059 20,310 -1,783 -1,121 500 -3,343
Enterprise Value (EV)		 104,457 103,699 65,444 69,388 60,616 67,097 86,575 100,871 117,171 113,455 131,754
Market Capitalization		 103,371 107,271 71,002 72,481 64,659 68,219 63,064 82,010 99,602 96,979 115,118
Book Value per Share		 $10.22 $12.86 $14.34 $15.65 $16.53 $17.80 $14.52 $16.80 $16.93 $18.32 $15.51
Tangible Book Value per Share		 $2.11 $4.94 $6.64 ($0.63) $1.18 $3.65 ($18.37) ($16.52) ($12.73) ($9.58) ($7.17)
Total Capital		 28,238 41,170 45,709 54,043 48,856 47,243 49,623 47,759 46,439 47,736 45,957
Total Debt		 12,404 22,055 26,346 33,542 27,322 24,593 31,402 26,695 25,230 24,987 26,711
Total Long-Term Debt		 11,921 21,073 26,346 30,795 24,574 22,094 28,645 25,179 22,957 23,189 24,896
Net Debt		 678 -4,153 -6,034 -3,152 -4,190 -1,247 23,492 18,866 17,600 16,560 16,720
Capital Expenditures (CapEx)		 557 747 748 590 924 825 650 579 728 585 523
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2,308 1,247 -1,525 -2,575 -2,110 -1,316 -52 -1,842 -906 -661 -1,007
Debt-free Net Working Capital (DFNWC)		 12,436 15,854 10,370 22,935 27,979 23,036 7,356 4,678 5,479 6,603 8,984
Net Working Capital (NWC)		 11,953 14,872 10,370 20,188 25,231 20,537 4,599 3,162 3,206 4,805 7,169
Net Nonoperating Expense (NNE)		 332 446 423 204 281 -908 128 1,229 1,191 609 674
Net Nonoperating Obligations (NNO)		 678 -4,153 -6,034 -3,152 -4,190 -1,247 23,492 18,866 17,600 16,560 16,720
Total Depreciation and Amortization (D&A)		 1,050 1,098 1,158 1,286 1,429 1,404 1,480 2,050 2,103 2,693 2,767
Debt-free, Cash-free Net Working Capital to Revenue		 9.27% 3.82% -5.02% -9.86% -9.54% -5.86% -0.21% -6.75% -3.32% -2.44% -3.50%
Debt-free Net Working Capital to Revenue		 49.96% 48.57% 34.12% 87.85% 126.45% 102.61% 29.79% 17.13% 20.08% 24.35% 31.24%
Net Working Capital to Revenue		 48.02% 45.57% 34.12% 77.33% 114.03% 91.48% 18.63% 11.58% 11.75% 17.72% 24.93%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $7.95 $12.37 $10.08 $3.54 $4.20 $4.24 $0.10 $4.96 $3.66 $4.54 $0.38
Adjusted Weighted Average Basic Shares Outstanding		 1.52B 1.46B 1.34B 1.31B 1.30B 1.27B 1.26B 1.26B 1.26B 1.25B 1.25B
Adjusted Diluted Earnings per Share		 $7.35 $11.91 $9.94 $3.51 $4.17 $4.22 $0.10 $4.93 $3.64 $4.50 $0.38
Adjusted Weighted Average Diluted Shares Outstanding		 1.65B 1.52B 1.36B 1.32B 1.31B 1.28B 1.26B 1.26B 1.26B 1.26B 1.26B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.49B 1.37B 1.31B 1.31B 1.28B 1.26B 1.26B 1.25B 1.25B 1.25B 1.25B
Normalized Net Operating Profit after Tax (NOPAT)		 12,391 18,552 13,911 9,887 5,741 3,001 2,850 7,430 7,877 6,263 4,056
Normalized NOPAT Margin		 49.78% 56.84% 45.77% 37.87% 25.94% 13.37% 11.54% 27.21% 28.87% 23.10% 14.10%
Pre Tax Income Margin		 59.69% 66.36% 56.26% 51.82% 35.25% 22.99% 6.76% 30.32% 21.31% 25.30% 2.40%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 37.06 32.48 18.74 13.10 8.24 6.19 2.70 9.27 7.22 8.27 1.71
NOPAT to Interest Expense		 30.08 26.97 14.43 4.34 5.33 4.48 0.22 7.42 6.16 6.59 1.18
EBIT Less CapEx to Interest Expense		 35.71 31.40 17.96 12.57 7.38 5.36 2.04 8.69 6.44 7.65 1.17
NOPAT Less CapEx to Interest Expense		 28.72 25.88 13.65 3.81 4.47 3.65 -0.44 6.84 5.38 5.97 0.65
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -0.29% 10.35% 18.20% 58.81% 54.41% 60.07% 3,875.28% 58.14% 81.23% 67.86% 816.25%
Augmented Payout Ratio		 44.07% 65.59% 99.76% 79.35% 107.53% 92.67% 5,653.93% 66.94% 111.80% 85.68% 1,055.83%

Quarterly Metrics And Ratios for Gilead Sciences

This table displays calculated financial ratios and metrics derived from Gilead Sciences' official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 2.00% -3.61% 5.42% 0.13% -3.72% 5.26% 5.38% 7.01% 6.40% -0.28% 1.84%
EBITDA Growth		 81.79% 255.32% 10.04% 1.54% -6.93% -263.10% 19.42% -41.76% 19.95% 173.57% 13.07%
EBIT Growth		 126.38% 1,680.23% 4.13% -4.13% -15.64% -376.36% 25.98% -53.19% 26.89% 145.12% 17.17%
NOPAT Growth		 291.43% 835.86% -28.90% 17.97% -24.19% -334.43% 90.93% -52.65% 45.92% 158.96% -3.97%
Net Income Growth		 334.31% 8,108.33% -8.46% 21.61% -13.23% -523.35% 55.34% -42.31% 25.83% 131.53% 21.44%
EPS Growth		 330.00% 3,900.00% -8.79% 21.83% -11.63% -517.50% 55.42% -42.20% 25.44% 131.14% 20.93%
Operating Cash Flow Growth		 -19.91% -5.22% 29.74% -38.70% -15.50% 27.24% -43.33% 145.53% 37.16% -20.82% -37.58%
Free Cash Flow Firm Growth		 30.91% -53.95% -52.86% -48.85% -70.04% -217.42% -24.51% 45.32% 507.74% 282.68% 104.10%
Invested Capital Growth		 -2.81% -0.99% -2.77% -0.34% 1.29% -2.70% 1.13% -6.63% -8.50% -4.81% -3.51%
Revenue Q/Q Growth		 4.93% -14.03% 3.89% 6.85% 0.89% -6.02% 4.01% 8.50% 0.32% -11.92% 6.22%
EBITDA Q/Q Growth		 -12.59% -22.05% 15.06% 29.50% -19.88% -236.61% 184.24% -36.84% 65.02% -16.21% 29.48%
EBIT Q/Q Growth		 -15.18% -32.17% 18.68% 40.40% -25.36% -322.22% 154.10% -47.84% 102.35% -20.99% 40.49%
NOPAT Q/Q Growth		 -12.51% -29.20% -15.59% 125.61% -43.78% -318.94% 168.75% -44.04% 73.25% -11.53% 11.96%
Net Income Q/Q Growth		 -8.57% -39.68% 5.48% 109.05% -34.76% -394.28% 138.71% -22.37% 42.30% -26.25% 49.05%
EPS Q/Q Growth		 -9.15% -37.98% 3.75% 108.43% -34.10% -392.98% 138.62% -22.48% 43.00% -27.27% 50.00%
Operating Cash Flow Q/Q Growth		 -10.34% -32.06% 34.06% -24.94% 23.59% 2.31% -40.29% 225.21% -30.96% -40.94% -52.93%
Free Cash Flow Firm Q/Q Growth		 -41.89% -42.88% 29.66% 18.82% -65.96% -323.89% 183.36% 128.74% 42.35% -32.70% -6.86%
Invested Capital Q/Q Growth		 -1.34% 0.44% -1.64% 2.26% 0.27% -3.51% 2.23% -5.60% -1.74% 0.39% 3.62%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 81.11% 77.94% 78.15% 77.80% 70.62% 76.79% 77.80% 79.14% 79.11% 76.90% 78.81%
EBITDA Margin		 37.69% 34.18% 37.85% 45.88% 36.44% -52.96% 42.90% 24.97% 41.08% 39.07% 47.63%
Operating Margin		 30.68% 26.84% 25.23% 37.20% 22.66% -64.64% 38.02% 11.77% 32.40% 33.55% 34.93%
EBIT Margin		 30.55% 24.10% 27.53% 36.18% 26.76% -63.28% 32.92% 15.83% 31.92% 28.63% 37.87%
Profit (Net Income) Margin		 22.10% 15.51% 15.74% 30.80% 19.92% -62.37% 23.21% 16.61% 23.56% 19.72% 27.68%
Tax Burden Percent		 80.40% 75.77% 65.43% 93.70% 85.72% 92.96% 78.62% 131.07% 82.28% 79.75% 80.69%
Interest Burden Percent		 89.99% 84.91% 87.40% 90.87% 86.82% 106.03% 89.69% 80.07% 89.69% 86.38% 90.57%
Effective Tax Rate		 19.60% 24.31% 34.57% 6.30% 14.28% 0.00% 21.33% -31.07% 17.77% 20.25% 19.27%
Return on Invested Capital (ROIC)		 17.09% 14.03% 11.62% 24.31% 13.49% -32.30% 21.57% 11.52% 20.35% 20.77% 21.37%
ROIC Less NNEP Spread (ROIC-NNEP)		 16.05% 12.40% 11.35% 22.69% 13.69% -38.24% 19.11% 12.02% 18.95% 18.27% 21.17%
Return on Net Nonoperating Assets (RNNOA)		 13.85% 11.38% 10.02% 18.47% 10.64% -38.36% 18.39% 10.41% 15.02% 18.75% 21.52%
Return on Equity (ROE)		 30.94% 25.40% 21.64% 42.78% 24.12% -70.67% 39.96% 21.93% 35.37% 39.52% 42.89%
Cash Return on Invested Capital (CROIC)		 17.47% 18.19% 18.94% 17.28% 14.65% 4.48% 3.33% 8.27% 11.95% 24.33% 22.10%
Operating Return on Assets (OROA)		 12.71% 10.43% 12.04% 15.86% 11.58% -29.40% 15.79% 7.66% 15.16% 14.60% 20.00%
Return on Assets (ROA)		 9.20% 6.71% 6.89% 13.51% 8.62% -28.98% 11.13% 8.04% 11.18% 10.06% 14.62%
Return on Common Equity (ROCE)		 30.97% 25.45% 21.69% 42.88% 24.19% -70.93% 40.11% 22.01% 35.51% 39.71% 43.08%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 26.38% 25.73% 26.12% 0.00% 2.61% 5.65% 0.62% 0.00% 31.13% 0.00%
Net Operating Profit after Tax (NOPAT)		 1,823 1,291 1,089 2,458 1,382 -3,025 2,080 1,164 2,016 1,784 1,997
NOPAT Margin		 24.67% 20.32% 16.51% 34.86% 19.42% -45.25% 29.91% 15.43% 26.64% 26.76% 28.20%
Net Nonoperating Expense Percent (NNEP)		 1.04% 1.63% 0.28% 1.62% -0.21% 5.94% 2.46% -0.51% 1.40% 2.50% 0.19%
Return On Investment Capital (ROIC_SIMPLE)		 3.93% - - - 2.89% - - - 4.39% 4.05% 4.48%
Cost of Revenue to Revenue		 18.89% 22.06% 21.85% 22.20% 29.38% 23.21% 22.20% 20.86% 20.89% 23.10% 21.19%
SG&A Expenses to Revenue		 27.34% 20.77% 28.02% 18.65% 22.59% 20.57% 19.80% 18.99% 25.18% 18.87% 19.27%
R&D to Revenue		 23.09% 30.35% 24.90% 21.95% 24.66% 84.52% 19.97% 25.18% 21.54% 24.48% 21.91%
Operating Expenses to Revenue		 50.43% 51.12% 52.92% 40.60% 47.95% 141.43% 39.78% 67.37% 46.72% 43.35% 43.87%
Earnings before Interest and Taxes (EBIT)		 2,257 1,531 1,817 2,551 1,904 -4,231 2,289 1,194 2,416 1,909 2,682
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2,785 2,171 2,498 3,235 2,592 -3,541 2,983 1,884 3,109 2,605 3,373
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.69 4.68 4.36 4.02 4.25 5.14 4.68 5.65 5.96 7.28 7.01
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 3.65 3.64 3.37 3.27 3.58 3.28 3.07 3.69 4.00 4.86 4.78
Price to Earnings (P/E)		 21.69 17.62 16.82 15.26 17.12 185.91 81.10 821.89 239.83 23.39 21.85
Dividend Yield		 3.68% 3.73% 4.00% 4.14% 3.85% 4.17% 4.43% 3.65% 3.33% 2.77% 2.81%
Earnings Yield		 4.61% 5.68% 5.94% 6.55% 5.84% 0.54% 1.23% 0.12% 0.42% 4.27% 4.58%
Enterprise Value to Invested Capital (EV/IC)		 3.02 2.98 2.85 2.72 2.89 2.91 2.73 3.35 3.66 4.33 4.16
Enterprise Value to Revenue (EV/Rev)		 4.30 4.30 4.00 3.89 4.18 4.03 3.81 4.33 4.58 5.45 5.39
Enterprise Value to EBITDA (EV/EBITDA)		 13.24 11.17 10.29 9.97 10.81 23.11 20.11 31.27 29.71 14.79 14.19
Enterprise Value to EBIT (EV/EBIT)		 17.36 14.20 13.24 13.06 14.54 54.17 42.17 105.98 78.99 20.04 18.98
Enterprise Value to NOPAT (EV/NOPAT)		 20.35 17.27 17.44 16.02 18.23 164.50 61.70 230.09 114.19 21.78 22.06
Enterprise Value to Operating Cash Flow (EV/OCF)		 12.92 12.96 11.50 12.68 14.17 13.04 14.19 12.22 12.17 15.10 15.77
Enterprise Value to Free Cash Flow (EV/FCFF)		 17.04 16.32 14.86 15.70 19.83 64.16 82.57 39.10 29.30 17.37 18.49
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.19 1.21 1.20 1.12 1.10 1.44 1.28 1.26 1.39 1.31 1.27
Long-Term Debt to Equity		 1.08 1.10 1.01 1.04 1.02 1.23 1.18 1.17 1.29 1.16 1.13
Financial Leverage		 0.86 0.92 0.88 0.81 0.78 1.00 0.96 0.87 0.79 1.03 1.02
Leverage Ratio		 3.10 3.06 3.03 2.89 2.85 3.08 2.95 2.88 2.88 3.09 2.89
Compound Leverage Factor		 2.79 2.60 2.65 2.62 2.47 3.26 2.65 2.30 2.59 2.67 2.62
Debt to Total Capital		 54.33% 54.66% 54.48% 52.90% 52.34% 59.07% 56.20% 55.83% 58.12% 56.67% 56.01%
Short-Term Debt to Total Capital		 4.89% 4.94% 8.71% 3.80% 3.77% 8.60% 4.36% 4.35% 3.95% 6.37% 6.30%
Long-Term Debt to Total Capital		 49.43% 49.71% 45.77% 49.10% 48.58% 50.47% 51.84% 51.48% 54.17% 50.30% 49.71%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.07% -0.13% -0.14% -0.15% -0.18% -0.20% -0.20% -0.20% -0.18% -0.19% -0.19%
Common Equity to Total Capital		 45.74% 45.47% 45.66% 47.25% 47.83% 41.12% 44.00% 44.37% 42.06% 43.52% 44.18%
Debt to EBITDA		 2.85 2.42 2.37 2.34 2.38 5.27 4.43 5.93 6.02 2.36 2.27
Net Debt to EBITDA		 1.99 1.73 1.62 1.59 1.58 4.28 3.91 4.65 3.77 1.61 1.62
Long-Term Debt to EBITDA		 2.59 2.20 1.99 2.17 2.21 4.50 4.09 5.47 5.61 2.09 2.02
Debt to NOPAT		 4.38 3.75 4.02 3.76 4.02 37.49 13.60 43.67 23.15 3.47 3.54
Net Debt to NOPAT		 3.06 2.68 2.75 2.55 2.66 30.47 11.98 34.21 14.49 2.37 2.53
Long-Term Debt to NOPAT		 3.99 3.41 3.38 3.49 3.73 32.03 12.54 40.26 21.58 3.08 3.14
Altman Z-Score		 2.38 2.36 2.22 2.35 2.48 1.92 2.44 2.68 2.78 3.23 3.33
Noncontrolling Interest Sharing Ratio		 -0.09% -0.17% -0.20% -0.22% -0.26% -0.37% -0.37% -0.38% -0.40% -0.46% -0.45%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.29 1.28 1.02 1.34 1.43 1.08 1.14 1.26 1.60 1.37 1.32
Quick Ratio		 0.99 0.95 0.78 0.98 1.06 0.72 0.69 0.82 1.20 1.00 0.89
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 2,944 1,682 2,180 2,591 882 -1,974 1,646 3,765 5,359 3,607 3,359
Operating Cash Flow to CapEx		 1,418.23% 1,600.00% 1,682.01% 1,438.52% 1,008.84% 2,113.33% 1,019.23% 3,056.03% 2,023.81% 1,689.42% 772.90%
Free Cash Flow to Firm to Interest Expense		 13.03 7.31 9.48 11.17 3.50 -7.77 6.94 15.82 21.61 13.87 13.23
Operating Cash Flow to Interest Expense		 11.36 7.58 10.17 7.56 8.61 8.74 5.59 18.11 12.00 6.76 3.26
Operating Cash Flow Less CapEx to Interest Expense		 10.56 7.11 9.56 7.04 7.75 8.32 5.04 17.51 11.40 6.36 2.83
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.42 0.43 0.44 0.44 0.43 0.46 0.48 0.48 0.47 0.51 0.53
Accounts Receivable Turnover		 5.89 6.80 6.56 5.99 5.75 6.22 6.25 6.04 6.33 6.35 6.11
Inventory Turnover		 3.62 3.68 3.60 3.71 3.95 3.88 3.69 3.83 3.58 3.45 3.22
Fixed Asset Turnover		 5.15 5.04 5.05 5.02 5.03 5.08 5.11 5.16 5.36 5.35 5.34
Accounts Payable Turnover		 7.03 9.31 9.49 9.67 8.93 10.65 11.65 9.08 9.04 9.18 11.07
Days Sales Outstanding (DSO)		 62.01 53.64 55.63 60.92 63.51 58.71 58.36 60.47 57.63 57.52 59.71
Days Inventory Outstanding (DIO)		 100.82 99.06 101.29 98.29 92.51 94.12 98.91 95.35 102.10 105.66 113.43
Days Payable Outstanding (DPO)		 51.94 39.20 38.45 37.73 40.86 34.28 31.33 40.20 40.38 39.75 32.96
Cash Conversion Cycle (CCC)		 110.89 113.51 118.47 121.49 115.16 118.55 125.95 115.63 119.35 123.43 140.18
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 38,809 38,980 38,340 39,205 39,309 37,929 38,774 36,604 35,966 36,106 37,412
Invested Capital Turnover		 0.69 0.69 0.70 0.70 0.69 0.71 0.72 0.75 0.76 0.78 0.76
Increase / (Decrease) in Invested Capital		 -1,121 -391 -1,091 -133 500 -1,051 434 -2,601 -3,343 -1,823 -1,362
Enterprise Value (EV)		 117,171 116,329 109,435 106,538 113,455 110,559 105,972 122,508 131,754 156,483 155,650
Market Capitalization		 99,602 98,347 92,254 89,648 96,979 90,167 85,478 104,380 115,118 139,541 137,914
Book Value per Share		 $16.93 $16.84 $16.96 $17.91 $18.32 $14.07 $14.67 $14.84 $15.51 $15.39 $15.82
Tangible Book Value per Share		 ($12.73) ($12.56) ($11.95) ($10.56) ($9.58) ($11.39) ($10.33) ($8.34) ($7.17) ($6.83) ($5.79)
Total Capital		 46,439 46,178 46,340 47,224 47,736 42,649 41,547 41,639 45,957 44,030 44,536
Total Debt		 25,230 25,239 25,246 24,982 24,987 25,194 23,350 23,249 26,711 24,952 24,946
Total Long-Term Debt		 22,957 22,956 21,209 23,189 23,189 21,527 21,540 21,437 24,896 22,146 22,140
Net Debt		 17,600 18,040 17,245 16,962 16,560 20,476 20,578 18,212 16,720 17,026 17,820
Capital Expenditures (CapEx)		 181 109 139 122 215 105 130 141 147 104 107
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -906 -661 -2,307 -1,036 -661 -25 574 -171 -1,007 -563 1,122
Debt-free Net Working Capital (DFNWC)		 5,479 5,211 4,360 5,828 6,603 4,693 3,346 4,866 8,984 7,363 6,335
Net Working Capital (NWC)		 3,206 2,928 323 4,035 4,805 1,026 1,536 3,054 7,169 4,557 3,529
Net Nonoperating Expense (NNE)		 190 306 50 286 -35 1,145 466 -89 233 469 37
Net Nonoperating Obligations (NNO)		 17,600 18,041 17,246 16,963 16,560 20,474 20,577 18,214 16,720 17,028 17,822
Total Depreciation and Amortization (D&A)		 528 640 681 684 688 690 694 690 693 696 691
Debt-free, Cash-free Net Working Capital to Revenue		 -3.32% -2.44% -8.43% -3.78% -2.44% -0.09% 2.06% -0.60% -3.50% -1.96% 3.89%
Debt-free Net Working Capital to Revenue		 20.08% 19.27% 15.92% 21.28% 24.35% 17.10% 12.03% 17.20% 31.24% 25.62% 21.95%
Net Working Capital to Revenue		 11.75% 10.83% 1.18% 14.73% 17.72% 3.74% 5.52% 10.79% 24.93% 15.86% 12.23%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.30 $0.81 $0.84 $1.75 $1.14 ($3.34) $1.29 $1.00 $1.43 $1.06 $1.57
Adjusted Weighted Average Basic Shares Outstanding		 1.26B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B
Adjusted Diluted Earnings per Share		 $1.29 $0.80 $0.83 $1.73 $1.14 ($3.34) $1.29 $1.00 $1.43 $1.04 $1.56
Adjusted Weighted Average Diluted Shares Outstanding		 1.26B 1.26B 1.26B 1.26B 1.26B 1.25B 1.25B 1.25B 1.26B 1.26B 1.26B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.24B 1.25B 1.25B 1.24B 1.24B
Normalized Net Operating Profit after Tax (NOPAT)		 1,823 1,291 1,089 2,458 1,425 -1,324 2,080 1,847 2,016 1,784 2,151
Normalized NOPAT Margin		 24.67% 20.32% 16.51% 34.86% 20.03% -19.81% 29.91% 24.47% 26.64% 26.76% 30.37%
Pre Tax Income Margin		 27.49% 20.47% 24.06% 32.87% 23.24% -67.10% 29.52% 12.67% 28.63% 24.73% 34.30%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 9.99 6.66 7.90 11.00 7.56 -16.66 9.66 5.02 9.74 7.34 10.56
NOPAT to Interest Expense		 8.07 5.61 4.74 10.59 5.48 -11.91 8.78 4.89 8.13 6.86 7.86
EBIT Less CapEx to Interest Expense		 9.19 6.18 7.30 10.47 6.70 -17.07 9.11 4.42 9.15 6.94 10.14
NOPAT Less CapEx to Interest Expense		 7.26 5.14 4.13 10.07 4.63 -12.32 8.23 4.30 7.54 6.46 7.44
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 81.23% 67.39% 69.02% 64.87% 67.86% 836.24% 373.48% 3,410.53% 816.25% 66.02% 62.75%
Augmented Payout Ratio		 111.80% 93.46% 96.99% 93.03% 85.68% 1,054.59% 465.44% 4,243.86% 1,055.83% 90.83% 92.96%

Key Financial Trends

Gilead Sciences (NASDAQ: GILD) shows a mixed financial performance over the last four years, with some positive signs as well as certain concerns observed in the recent quarters.

Positive trends and highlights:

  • Operating revenue generally trends upward from $6.35B in Q1 2023 to a peak of $7.57B in Q4 2024, before a slight dip to $6.67B in Q1 2025, indicating strong sales generation capacity.
  • Gross profit has remained solid, with recent Q1 2025 gross profit at approximately $5.13B, reflecting efficient cost management of revenues.
  • Net income rebounded from a significant loss in Q1 2024 (-$4.17B) to positive figures in subsequent quarters, reaching $1.32B in Q1 2025, signaling recovery in profitability.
  • Diluted EPS recovered similarly, from -$3.34 in Q1 2024 to $1.04 in Q1 2025.
  • Operating cash flow remains positive and stable. For example, Q1 2025 operating cash flow was $1.76B, highlighting strong cash-generating ability from core operations.
  • Gilead maintains a strong cash and equivalents position, with over $7.9B at quarter-end Q1 2025, supporting liquidity and flexibility.
  • Consistent payment of dividends (~$0.75 to $0.79 per share) suggests steady shareholder returns.
  • Relatively stable share count around 1.25 billion shares outstanding, indicating limited dilution.

Neutral observations:

  • Acquisition activity has been consistent, with investments around $150M - $790M in recent quarters, which could support future growth but also impacts cash flow.
  • Capital expenditures on property, plant, and equipment have ranged around $100M - $215M, reflecting ongoing investments in infrastructure.

Negative factors and concerns:

  • Q1 2024 shows a large impairment charge of $2.43B, leading to a net loss of $4.17B and negative operating income, indicating one-off costs impacting earnings that quarter.
  • Interest expense remains high at approximately $230M - $260M per quarter, indicating significant debt burden.
  • Overall liabilities remained high, with total liabilities around $37.3B in Q1 2025, compared to total equity of $19.1B, suggesting a leveraged balance sheet position.
  • Total operating expenses, including R&D, SG&A, and impairments, have occasionally been elevated, pressuring operating income margins.
  • Negative net cash flow from financing activities in Q1 2025 (-$3.43B) primarily due to debt repayment and share repurchases, indicating return of capital but also cash outflow pressure.

Summary: Gilead Sciences experienced a challenging start in early 2024 with large impairments resulting in losses, but has since returned to profitability and positive cash flows by Q1 2025. The company demonstrates strong revenue generation, decent profitability recovery, healthy operating cash flow, and consistent shareholder dividends. However, the firm carries high liabilities with considerable interest costs and ongoing investments that may impact future earnings. Investors should watch management's ability to sustain earnings growth, manage debt, and capitalize on acquisitions and R&D investments going forward.

08/08/25 10:29 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Gilead Sciences' Financials

When does Gilead Sciences' financial year end?

According to the most recent income statement we have on file, Gilead Sciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Gilead Sciences' net income changed over the last 10 years?

Gilead Sciences' net income appears to be on a downward trend, with a most recent value of $480 million in 2024, falling from $12.06 billion in 2014. The previous period was $5.61 billion in 2023. Check out Gilead Sciences' forecast to explore projected trends and price targets.

What is Gilead Sciences' operating income?
Gilead Sciences' total operating income in 2024 was $1.66 billion, based on the following breakdown:
  • Total Gross Profit: $22.50 billion
  • Total Operating Expenses: $20.84 billion
How has Gilead Sciences' revenue changed over the last 10 years?

Over the last 10 years, Gilead Sciences' total revenue changed from $24.89 billion in 2014 to $28.75 billion in 2024, a change of 15.5%.

How much debt does Gilead Sciences have?

Gilead Sciences' total liabilities were at $39.75 billion at the end of 2024, a 0.9% increase from 2023, and a 111.1% increase since 2014.

How much cash does Gilead Sciences have?

In the past 10 years, Gilead Sciences' cash and equivalents has ranged from $5.34 billion in 2021 to $17.94 billion in 2018, and is currently $9.99 billion as of their latest financial filing in 2024.

How has Gilead Sciences' book value per share changed over the last 10 years?

Over the last 10 years, Gilead Sciences' book value per share changed from 10.22 in 2014 to 15.51 in 2024, a change of 51.7%.


Related Companies

This page (NASDAQ:GILD) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsored
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about Presi...
InvestorPlace | Sponsored
Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...
Paradigm Press | Sponsored
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
Crypto 101 Media | Sponsored
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...
Brownstone Research | Sponsored
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsored
How high will gold surge?
Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...
Weiss Ratings | Sponsored
Gold Hit $3,500. Here’s What’s Next…
Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...
Reagan Gold Group | Sponsored